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Editorial on the Research Topic
Advances in Steroid-Responsive Encephalopathy
In neurology, “steroid-responsive encephalopathy” is a general term for diseases characterized by
diffuse brain injury and responsiveness to steroids. These diseases include autoimmune encephalitis
(AE), Hashimoto’s encephalopathy (HE), limbic encephalitis, and anti-neutrophil cytoplasmic
antibody (ANCA)-associated vacuities encephalopathy, among others. These diseases are
common and complicated in clinical management. Further understanding of their epidemiology,
pathophysiological mechanism, diagnosis, treatment and prognosis from various perspectives can
help improve the insights of clinicians and researchers. To provide a platform for sharing the latest
research findings in steroid-responsive encephalopathy, we organized this special issue, in which
11 manuscripts have been accepted for publication, including 6 original research articles, four
reviews, and one mini review. To a certain extent, these manuscripts have expanded the current
understanding of such diseases.
To date, there have been few large-scale epidemiological investigations of AE in adults or
children, and its epidemiological characteristics remain unclear. Gu et al. provided a detailed
description of the epidemiological characteristics of 189 patients with antibody-positive AE
at six large general hospitals, and they also analyzed the differences in composition ratios,
ICU occupancy, ventilator use, tumor and surgery, and prognosis among different age groups,
gender groups, antibody groups, and disease characteristics. Separately, Qiu et al. retrospectively
analyzed clinical features, laboratory and imaging results, and predictors of poor prognosis
in 50 patients with an initial diagnosis of AE at their hospital. The authors found that the
neutrophil-to-lymphocyte ratio might have predictive value for poor outcomes in AE and that early
initiation of immunotherapy was associated with a good prognosis.
In a study focusing on pediatric AE, Zhang et al. retrospectively analyzed the clinical
characteristics of 103 children with AE in two Chinese tertiary pediatric neurology
centers, including 89 patients with anti-NMDA receptor (NMDAR) encephalitis, two with
anti-LGI1 encephalitis, one with anti-CASPR2 encephalitis, and 11 autoantibody-negative
patients with probable AE. Anti-NMDAR encephalitis is the most common form of
AE in pediatric patients. Another study by Zhang et al. analyzed the demographic
characteristics, clinical features, treatment, and outcomes of 34 children with anti-
NMDAR encephalitis treated at Children’s Hospital of Fudan University. The authors
found that most of the included children were sensitive to first-line immunotherapy
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and achieved good outcomes, and higher Modified Rankin
Scale scores before immunotherapy predicted poor outcomes.
In addition, the authors also concluded that long-term use of
antiepileptic drugs (AEDs) may not be necessary for pediatric
patients with anti-NMDAR encephalitis.
Many patients with encephalitis have seizures during the
development of the disease. Huang et al. followed up 75
outpatients with AE and reported in detail on the characteristics
of those patients’ seizures and their long-term use of AEDs. That
study compared outcomes between patients with early and late
AED withdrawal and determined the probable risk factors for
seizure relapse and refractory epilepsy. As in Zhang et al. findings
on pediatric anti-NMDAR encephalitis, these AE patients had a
high rate of seizure remission after proper immunotherapy, and
long-term use of AEDs may not be necessary to control their
seizures. Compared with adults, young patients are more likely
to become seizure free without AEDs. In addition, Huang et al.
also reported that patients with anti-GABAB receptor (GABABR)
antibodies, status epilepticus (SE), and cortical abnormalities
had an increased risk of developing refractory epilepsy or
seizure relapse.
A study by Lin et al. focused on the different clinical signs
of infectious and autoimmune SE. These two entities may
present with similar symptoms initially but require different
treatment strategies. Since the prognosis of SE largely depended
on etiology, faster-targeted treatment is required at the initial
encounter. On this basis, Lin et al. conducted a retrospective
study that included 501 patients with SE within a period of
10.5-years. Their study suggested that autoimmune SE had a
relatively early age of onset; that it occurred predominantly in
females; and that it often presented as psychosis, non-convulsive
SE, and super-refractory SE. A lymphocytic predominance in
cerebrospinal fluid was more commonly observed in patients
with autoimmune SE than in those with infectious SE. These
patient characteristics and signs may help clinicians select
initial investigations and ensuing therapies that may improve
overall outcomes.
HE has become increasingly recognized as an important and
treatable cause of AE. Seizure disorders were observed in ∼60–
70% of patients with HE, and often as the first manifestation
of the disease. HE is easily misdiagnosed because of the low
incidence and the atypical symptoms. The manuscript by Li et
al. discusses HE, the characteristic of its accompanying seizure
disorders and the appropriate diagnostic approach.
Many neurologists may have limited experience in treating
primary systemic vasculitis (PSV), mainly because most of
these patients are diagnosed and managed by rheumatologists.
However, PSV can affect every structure in both the central
and the peripheral nervous systems, causing various neurological
manifestations of dysfunction. Therefore, PSV patients may
sometimes be referred to a neurologist first. The clinical
manifestations of PSV are often non-specific, and differential
diagnosis may be difficult. With these considerations in mind,
Zhang et al. provide a comprehensive review of the clinical
manifestations of PSV in the nervous system.
ANCA-associated vasculitis (AAV) is a multisystem
inflammatory disease that can involve the central nervous
system (CNS). Treatment with steroids, sometimes combined
with immunosuppressants, can dramatically improve the
outcome. However, for neurologists, the wide clinical spectrum
of CNS involvement often complicates the diagnosis and thus
delays treatment. Thus, Zheng et al. reviewed the manifestations
of CNS involvement in AAV and emphasized ANCA testing,
a crucial AAV diagnostic that requires appropriate result
interpretation; the authors hoped to increase awareness
and expand understanding of AAV-related CNS diseases
among neurologists.
Immunoglobulin formulations have been used in an
increasing number of diseases. In most cases, such formulations
are safe and well-tolerated, but an increasing number of studies
have reported potentially adverse effects of immunoglobulin
treatment, some of which are severe and even fatal. In Guo et al. ’s
manuscript, the authors reviewed the incidence, risk factors and
clinical characteristics of these adverse immunoglobulin-induced
effects and addressed methods to minimize and prevent them.
Plasma exchange is widely used in the treatment of
neurological diseases in which autoimmune mechanisms
play a leading role. A growing body of research suggests
that in the clinical treatment of steroid-responsive
encephalopathies such as HE, limbic encephalitis, systemic
lupus erythematosus encephalopathy, and ANCA-associated
vacuities encephalopathy, plasma exchange is a safe and effective
option when steroids or other immunosuppressive therapies
are ineffective in the short term or when contraindications are
present. A study by Jiang et al. provides a detailed review
of the indications, onset time, course, curative effects,
and side effects of plasmapheresis as applied clinically to
steroid-responsive encephalopathy.
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